Atara Biotherapeutics (ATRA) Other Accumulated Expenses (2013 - 2026)

Atara Biotherapeutics (ATRA) has 14 years of Other Accumulated Expenses data on file, last reported at $2.9 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 64.83% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (up 64.83% YoY) and the FY2025 annual result came in at $82000.0, down 98.97% from the prior year.
• Other Accumulated Expenses climbed to $2.9 million in Q1 2026, from $82000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $31.8 million in Q4 2023 to a low of $82000.0 in Q4 2025.
• A 5-year average of $11.7 million and a median of $8.0 million in 2024 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 7165.12% — and 2025, when it plunged 98.97%.
• Tracing ATRA's Other Accumulated Expenses over 5 years: stood at $25.0 million in 2022, then gained by 27.34% to $31.8 million in 2023, then sank by 74.91% to $8.0 million in 2024, then sank by 98.97% to $82000.0 in 2025, then surged by 3484.15% to $2.9 million in 2026.
• The last three Other Accumulated Expenses figures came in at $2.9 million (Q1 2026), $82000.0 (Q4 2025), and $144000.0 (Q3 2025), per Business Quant data.